> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 use with raised CRP tracked lower mortality but no change in heart attacks
- URL: https://www.coios.me/glp-1-use-with-raised-crp-tracked-lower-mortality-but-no/
- Published: 2026-09-23T13:00:01.000Z
- Updated: 2026-09-23T21:35:23.000Z
- Description: In a matched cohort of 100,018 US adults with obesity and raised C-reactive protein, GLP-1 exposure was associated with a lower composite of death, myocardial infarction and stroke (HR 0.80), almost entirely through all-cause mortality (HR 0.61), with no difference in infarction.
- Author: Daniel Ryan
- Tags: Healthcare today, Cardiovascular disease, Obesity, diabetes and the GLP-1 drugs, World, #peer-reviewed, #confirms, #item, #source-2026-09

Adults with a body mass index of 30 or above and C-reactive protein of 3 to 10 mg/L who received a GLP-1 receptor agonist were matched one to one with adults receiving metformin, orlistat or phentermine in the TriNetX electronic health record network, 50,009 in each arm, followed for up to ten years. The composite of death, acute myocardial infarction and ischaemic stroke was lower with GLP-1 exposure (HR 0.80, 95% CI 0.77-0.83), driven by all-cause mortality (HR 0.61, 0.58-0.64). Ischaemic stroke, arrhythmias and heart failure with reduced ejection fraction were modestly lower, while myocardial infarction did not differ.

*Why it is interesting: The mortality hazard ratio is far larger than any randomised trial has shown and the infarction result is null, so the gap between the two is the thing to weigh.*

Source

[The American Journal of Cardiology, 21 September 2026](https://doi.org/10.1016/j.amjcard.2026.09.016?ref=coios.me)

DOI

10.1016/j.amjcard.2026.09.016

Type

Peer-reviewed article

Design

Propensity-matched active-comparator cohort in the TriNetX federated EHR network, 50,009 per arm, followed up to 10 years

Verdict

Confirms prior evidence

Driver

[Cardiovascular disease](https://www.coios.me/d-cardiovascular/)

Driver

[Obesity, diabetes and the GLP-1 drugs](https://www.coios.me/d-obesity-diabetes/)